ZimVie Inc. When-Issued (ZIMVV) Peer Comparison
$24.17
$0.48
(2.03%)
As on 22-Apr-2022 09:30EDT
Market cap
$992 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Edit
| ZimVie Inc. When-Issued (ZIMVV) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
992 | 12,650 | 12,007 | 10,638 | 9,762 |
Revenue ($ Mln) |
912 | 1,505 | 6,164 | 613 | 2,589 |
Net Profit ($ Mln) |
-179.10 | 160.59 | 625.00 | -188.05 | 222.40 |
Net Margin (%) |
-- | 10.67 | 5.41 | -30.68 | 8.59 |
RoE (%) |
-11.34 | 10.86 | 11.84 | -28.10 | 3.04 |
Price to Earnings |
-- | 79.29 | 19.52 | -- | 44.47 |
Price-To-Book |
0.45 | 8.31 | 2.34 | 15.27 | 1.36 |
Income Statement ($ Mln)
| ZimVie Inc. When-Issued (ZIMVV) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Operating Revenue
|
912.40 | 560.41 | 4,560.00 | 224.96 | 2,545.63 |
|
Cost of Revenue
|
312.90 | 222.24 | 1,381.00 | 91.72 | 1,107.74 |
|
Gross Profit
|
599.50 | 338.18 | 3,179.00 | 133.24 | 1,437.89 |
|
Operating Expenses
|
981.10 | 377.12 | 2,884.00 | 256.79 | 1,016.56 |
|
Operating Profit (EBIT)
|
-68.70 | -38.94 | 295.00 | -123.55 | 421.33 |
|
Other Income
|
-- | -0.34 | -- | 2.38 | 22.72 |
|
Profit before Tax
|
-221.30 | -38.02 | 246.00 | -132.31 | 4,918.01 |
|
Provision for Tax
|
-- | -18.76 | -202.00 | -11.97 | 1,103.78 |
|
Profit after Tax (Net Income)
|
-179.10 | -19.26 | 448.00 | -120.35 | 3,814.23 |
|
Minority Interest
|
-- | -3.71 | -- | -- | -- |
|
Consolidated Profit
|
-- | -15.70 | 448.00 | -120.35 | 3,806.27 |
Liabilities ($ Mln)
| ZimVie Inc. When-Issued (ZIMVV) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,490.50 | 641.50 | 5,279.00 | 667.45 | 9,879.94 |
|
Minority Interest
|
-- | -3.71 | -- | -- | -- |
|
Non-Current Liabilities
|
232.50 | 79.26 | 4,045.00 | 288.35 | 2,461.14 |
|
Current Liabilities
|
226.20 | 105.93 | 1,688.00 | 49.70 | 631.54 |
|
Total Liabilities
|
1,949.20 | 822.98 | 11,012.00 | 1,005.50 | 12,972.62 |
Assets ($ Mln)
| ZimVie Inc. When-Issued (ZIMVV) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,423.20 | 205.28 | 6,348.00 | 536.06 | 10,832.77 |
|
Current Assets
|
526.00 | 617.70 | 4,664.00 | 469.44 | 2,139.84 |
|
Total Assets
|
-- | 822.98 | 11,012.00 | 1,005.50 | 12,972.62 |
|
Total Debt*
|
-- | 77.28 | 3,690.00 | 272.00 | 225.74 |
|
Net Current Assets
|
299.80 | 511.77 | 2,976.00 | 419.74 | 1,508.30 |
Cashflow ($ Mln)
| ZimVie Inc. When-Issued (ZIMVV) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
86.00 | -33.24 | 935.00 | -22.99 | 584.97 |
|
Cash Flow from Investing Activities
|
-- | -104.15 | -606.00 | -205.06 | -69.89 |
|
Cash from Financing Activities
|
-46.50 | 134.92 | 1,164.00 | 262.54 | -523.04 |
|
Net Cash Inflow / Outflow
|
-- | -2.47 | -- | 34.41 | 4.46 |
Ratios
Profitability Ratios
| ZimVie Inc. When-Issued (ZIMVV) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-11.34 | -2.99 | 5.55 | -14.28 | 46.20 |
|
ROE (%)
|
-11.34 | -3.42 | 8.60 | -17.95 | 48.79 |
|
ROA (%)
|
-8.82 | -2.59 | 4.41 | -13.20 | 36.36 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-19.63 | -3.44 | 9.82 | -52.94 | 148.51 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| ZimVie Inc. When-Issued (ZIMVV) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.14 | 0.02 | -0.11 | -0.05 | 0.10 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-539.64 | -139.74 | -25.33 | -880.26 | 116.88 |
|
EPS Growth (%)
|
-- | -1.39 | -0.26 | -8.51 | 1.17 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| ZimVie Inc. When-Issued (ZIMVV) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -340.37 | 82.87 | -28.17 | 4.54 |
|
Price / Book Value
|
-- | 10.22 | 7.03 | 5.08 | 1.75 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-- | -244.40 | 42.28 | -38.98 | 3.26 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| ZimVie Inc. When-Issued (ZIMVV) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-- | 0.12 | 0.70 | 0.41 | 0.02 |
|
Short term debt to equity ratio
|
-- | 0.01 | 0.06 | 0.00 | 0.00 |
|
Current Ratio
|
2.33 | 5.83 | 2.76 | 9.45 | 3.39 |
|
Quick Ratio
|
1.07 | 3.76 | 1.76 | 9.13 | 2.40 |
|
Interest Coverage
|
-- | -2.24 | 6.93 | -8.37 | 225.97 |
Operating Efficiency Ratios
| ZimVie Inc. When-Issued (ZIMVV) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
21.23 | 20.45 | 19.98 | 16.03 | 16.48 |
|
Asset Turnover
|
0.45 | 0.75 | 0.45 | 0.25 | 0.24 |
|
Receivable days
|
76.58 | 71.86 | 79.82 | 60.46 | 58.26 |
|
Inventory Days
|
323.17 | 306.12 | 437.06 | 116.26 | 193.92 |
|
Payable days
|
58.37 | 24.01 | 242.27 | 20.21 | 40.63 |
|
Cash Conversion Cycle
|
341.38 | 353.97 | 274.61 | 156.50 | 211.55 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
